

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/713,248
	Filing Date	November 13, 2003
	First Named Inventor	Jennie P. MATHER
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	12 + 34 Refs.	Attorney Docket Number 415072002300

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO-1449 (4 pages in duplicate) 2. References (34) 3. Return receipt postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Jie Zhou - 52,395
Signature	
Date	February 23, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 23, 2004

Signature: (Martina Placid)



PATENT
Docket No. 415072002300

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on February 23, 2004.

Martina Placid

Martina Placid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Jennie P. MATHER et al.

Serial No.: 10/713,248

Filing Date: November 13, 2003

For: ANTIGEN PIPA AND ANTIBODIES
THAT BIND THERETO

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted. However, copies of foreign documents and non-patent literature are being submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 415072002300. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 23, 2004

Respectfully submitted,

By: _____



Jie Zhou
Registration No. 52,395

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5922
Facsimile: (650) 494-0792



Form PTO-1449

Docket Number 415072002300

Application Number 10/713,248

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Jennie P. MATHER et al.

Filing Date November 13, 2003

Group Art Unit Not Yet Assigned

Mailing Date February 23, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	06/30/1987	4,676,980	Segal et al.			
	2.	03/28/1989	4,816,567	Cabilly et al.			
	3.	09/03/1996	5,552,391	Coutts et al.			
	4.	10/15/1996	5,565,332	Hoogenboom et al.			
	5.	12/03/1996	5,580,717	Dower et al.			
	6.	08/12/1997	5,656,444	Webb et al.			
	7.	09/09/1997	5,665,570	Yamagata et al.			
	8.	10/14/1997	5,677,425	Bodmer et al.			
	9.	03/31/1998	5,733,743	Johnson et al.			
	10.	06/02/1998	5,760,185	Kimachi et al.			
	11.	06/30/1998	5,773,247	Maeda et al.			
	12.	09/15/1998	5,807,715	Morrison et al.			
	13.	02/02/1999	5,866,692	Shitara et al.			
	14.	07/27/1999	5,929,212	Jolliffe et al.			
	15.	08/03/1999	5,932,225	Wallach et al.			
	16.	12/07/1999	5,997,867	Waldmann et al.			
	17.	04/25/2000	6,054,297	Carter et al.			
	18.	04/25/2000	6,054,561	Ring			
	19.	08/29/2000	6,110,724	Nakagomi et al.			
	20.	09/12/2000	6,117,653	Thoma			
	21.	01/30/2001	6,180,377	Morgan et al.			
	22.	04/04/2001	6,221,644	Berka et al.			
	23.	07/24/2001	6,265,150	Terstappen et al.			
	24.	12/18/2001	6,331,415	Cabilly et al.			
	25.	06/18/2002	6,406,840	Li et al.			
	26.	07/09/2002	6,416,999	Li et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

FEB 27 2004

Docket Number 415072002300

Application Number 10/713,248

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Jennie P. MATHER et al.

Filing Date November 13, 2003

Group Art Unit Not Yet Assigned

Mailing Date February 23, 2004

27.	08/27/2002	6,441,163	Chari et al.
-----	------------	-----------	--------------

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date		Country	Class	Subclass	Translation YES NO
	28.	12/23/1992	EP 0 519 596	Europe			

OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	29.	Aruffo, A. et al. (1987). "Molecular Cloning of a CD 28 cDNA by a High-Efficiency COS Cell Expression System," <i>Proc. Natl. Acad. Sci USA</i> 84:8573-8577.
	30.	Bird, R. E. et al. (1988). "Single-Chain Antigen-Binding Proteins," <i>Science</i> 242:423-426.
	31.	Brown, B. A et al. (1987). "Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody," <i>Cancer Res.</i> 47:3577-3583.
	32.	Carter, P. et al. (1992). "Humanization of an Anti-p185 ^{HER2} Antibody for Human Cancer Therapy," <i>Proc. Nat. Acad. Sci USA</i> 89:4285-4289.
	33.	Co, M. S. et al. (1991). "Humanized Antibodies for Antiviral Therapy," <i>Proc. Nat. Acad. Sci USA</i> 88:2869-2873.
	34.	Co, M. S. et al. (1992). "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen," <i>J. Immunol.</i> 148(4):1149-1154.
	35.	Coligan, J.E. et al., eds (1991). "Isolation of Proteins Using Antibodies," <i>In Current Protocols in Immunology</i> , John Wiley & Sons, Inc., Volume 2, Supplement 18, pp. 8.2.1-8.2.9.
	36.	Daugherty, B. L. et al. (1991). "Polymerase Chain Reaction Facilitates the Cloning, CDR-grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD 18 Component of Leukocyte Integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476.
	37.	Dillman, R. O. et al. (1988). "Superiority of an Acid-Labile Daunorubicin-Monoclonal Antibody Immunoconjugate Compared to Free Drug," <i>Cancer Research</i> 48:6097-6102.
	38.	Gorman, S. D. et al. (1991). "Reshaping a Therapeutic CD4 Antibody," <i>Proc. Nat. Acad. Sci USA</i> 88:4181-4185.
	39.	Jones, P. T. et al. (1986). "Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse," <i>Nature</i> 321:522-525.
	40.	Kettleborough, C. A et al. (1991). "Humanization of a Mouse Monoclonal Antibody by CDR-grafting: Importance of Framework Residues on Loop Conformation," <i>Protein Engineering</i> 4(7):773-783.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 415072002300	Application Number 10/713,248
	Applicant Jennie P. MATHER et al.	
	Filing Date November 13, 2003	Group Art Unit Not Yet Assigned
	Mailing Date February 23, 2004	

41.	Kohler, G. et al. (1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256:495-497.
42.	Lobuglio, A. F. et al. (1989). "Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response," <i>Proc. Natl. Acad. Sci. USA</i> 86:4220-4224.
43.	Lowe (1979). "An Introduction to Affinity Chromatography," <i>In Laboratory Techniques in Biochemistry and Molecular Biology</i> , North-Holland Publishing Company, Work, T. S. et al., eds., Volume 7 Part II, pp. 269-273 (Table of Contents Only).
44.	Maeda, H. et al. (1991). "Construction of Reshaped Human Antibodies with HIV-Neutralizing Activity," <i>Human Antibodies Hybridomas</i> 2:124-134.
45.	Mahato, R. I. et al. (1997). "Cationic Lipic-Based Gene Delivery Systems: Pharmaceutical Perspectives," <i>Pharm. Res.</i> 14(7):853-859.
46.	Mangham D. C. et al. (1999). "A Novel Immunohistochemical Detection System Using Mirror Image Complementary Antibodies (MICA)," <i>Histopathology</i> 35(2):129-133.
47.	Porath, J. et al. (1975). "Biospecific Affinity Chromatography and Related Methods," Chapter 2 <i>In The Proteins</i> , 3 rd edition, Neurath, H. et al., eds. Academic Press, Volume 1 pp. 95-178.
48.	Riechmann, L. et al. (1988). "Reshaping Human Antibodies for Therapy," <i>Nature</i> 332:323-327
49.	Shaw, D. R et al (1987). "Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) to a Colon Cancer Tumor-Associated Antigen," <i>J. Immunol.</i> 138:4534-4538.
50.	Shen, W-C et al. (1981). "CIS-Aconityl Spacer Between Daunomycin and Macromolecular Carriers: A Model of Ph-Sensitive Linkage Releasing Drug From a Lysosomotropic Conjugate," <i>Biochem. Biophys Res. Commun</i> 102:1048-1054.
51.	Stephan, J-P et al. (1999). "Distribution and Function of the Adhesion Molecule BEN During Rat Development," <i>Dev. Bio.</i> 212:264-277.
52.	Stephan, J-P. et al. (1999). "Selective Cloning of Cell Surface Proteins Involved in Organ Development: Epithelial Glycoprotein Is Involved in Normal Epithelial Differentiation," <i>Endocrinology</i> 140(12):5841-5854.
53.	Tempest, P. R. et al. (1991). "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection <i>In Vivo</i> ," <i>Bio/Technology</i> 9:266-271.
54.	Trouet, A. et al. (1982). "A Covalent Linkage Between Daunorubicin and Proteins That is Stable in Serum and Reversible by Lysosomal Hydrolases, as Required for a Lysosomotropic Drug-Carrier Conjugate: <i>In Vitro</i> and <i>In Vivo</i> Studies," <i>Proc. Natl. Acad. Sci.</i> 79:626-629.
55.	Verhoeven, M. et al. (1988). "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <i>Science</i> 239:1534-1536.
56.	Weimer, L. M. et al. (2001). "Therapeutic Monoclonal Antibodies: General Principles," Chapter 20, Section 5 <i>In Cancer: Principles and Practice of Oncology</i> , 6 th Edition, Freeman, Jr., Stuart, J. et al., eds, Lippincott Williams & Wilkins, pp. 495-508.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 415072002300

Application Number 10/713,248

Applicant

Jennie P. MATHER et al.

Filing Date November 13, 2003

Group Art Unit Not Yet Assigned

Mailing Date February 23, 2004

- | | |
|-----|--|
| 57. | Wheatley, S. P. et al. (1998). "Indirect Immunofluorescence Microscopy in Cultured Cells," Chapter 18 <i>In Animal Cell Culture Methods</i> , Mather, J.P. and Barnes, eds, Academic Press, Inc. Vol 57, pp. 313-332. |
| 58. | Winter, G. et al. (1994). "Making Antibodies By Phage Display Technology," <i>Annual. Rev. Immunol.</i> 12:433-455. |
| 59. | Winter, G. et al. (1991). "Man-Made Antibodies," <i>Nature</i> 349:293-299. |
| 60. | Woodruff, T. K. (1998). "Cellular Localization of mRNA and Protein: <i>In Situ</i> Hybridization Histochemistry and <i>in Situ</i> Ligand Binding," Chapter 19 <i>In Animal Cell Culture Methods</i> , Mather, J.P. et al., eds, Academic Press, Inc. Vol 57, pp. 333-351. |
| 61. | Yang, H. M. et al. (1988). "Pharmacokinetics and Mechanism of Action of a Doxorubicin-Monoclonal Antibody 9.2.27 Conjugate Directed to a Human Melanoma Proteoglycan," <i>J. Natl. Can. Inst</i> 80:1154-1159. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.